摘要
目的探讨金刚烷胺治疗帕金森病(PD)左旋多巴诱导异动症(LID)的临床疗效。方法将42例帕金森病患者随机分为金刚烷胺组与恩托卡朋组,每组21例,每组均应用美多巴和普拉克索作为帕金森病基础治疗。经12 w联合用药治疗后,以统一帕金森病评定量表(UPDRS)各部分评分相对于基线(治疗前评分)的变化为指标评估疗效。同时监测血压,观察患者不良反应,比较两组治疗方案的安全性。结果经12 w治疗后金刚烷胺组UPDRS.IV(治疗的并发症)评分相对基线有显著下降.差异有统计学意义(P<0.05)。金刚烷胺组UPDRS.IV(治疗的并发症)评分较恩托卡朋组评分下降更多,差异有统计学意义(P<0.05)。金刚烷胺组临床总有效率为86%,恩托卡朋组临床总有效率为32%,差异有显著统计学意义(P<0.05)。两组药品不良反应发生率分别为19%和23%。差异无统计学意义(P>0.05)。结论金刚烷胺治疗左旋多巴诱导的帕金森病异动症可获得较显著的近期疗效。
Objective To investigate the efficacy,safety and tolerability of amantadine in Parkinson＇s disease patients suffering from dyskinesias. Methods Included in the present study were 42 PD patients with dyskinesia who received amantadine（ 300 mg /day） or Entacapone（ 300 mg /day） as an adjunct to levodopa and pramipexole for 12 weeks in our institute. The outcome measures were changes in the Unified Parkinson＇s Disease Rating Scale part IVa（ UPDRS-IVa,dyskinesias）,part IVb（ motor fluctuations）,and part III（ motor function） during each treatment period. The safety and tolerability were assessed on the basis of side effects and blood pressure. Results UPDRS-IVa was improved to a significantly greater degree in amantadine-treated patients compared with that of before treatment（ P〈 0. 01）,and UPDRS-IVa was also improved to a significantly greater degree in amantadine-treated patients compared with that of Entacapone-treated patients（ P〈 0.01）. However,there were no significant effects on UPDRS-IVb or III scores between two groups after treatment（ P〉 0. 05）. No significant difference was found between the amantadine and Entacapone groups in terms of adverse events（ 29%,33%）（ P〉 0.05）. Conclusions Results from the present study demonstrated that amantadine exhibited efficacious effects on dyskinesias in about 80% patients at least with short-term use and is well-tolerated in the treatment of PD patients with dyskinesias as an adjunct to levodopa and pramipexole.
出处
《中风与神经疾病杂志》
CAS
CSCD
北大核心
2014年第9期835-837,共3页
Journal of Apoplexy and Nervous Diseases
关键词
金刚烷胺
恩托卡朋
帕金森病
异动症
Amantadine
Entacapone
Parkinson＇s disease
Dyskinesias
